Why the study?
Does single-dose intravenous erythropoietin improve coronary microvascular dysfunction and myocardial viability in patients with first anterior AMI after successful PCI?
Does single-dose intravenous erythropoietin improve coronary microvascular dysfunction and myocardial viability in patients with first anterior AMI after successful PCI?
A single medium dose of intravenous erythropoietin after PCI for anterior AMI may improve coronary microvascular dysfunction and attenuate left atrial remodeling at 8 months.
Answers are grounded in this paper and cite their sources.
EPO after anterior AMI PCI may enhance microvascular function and limit remodeling; extends prior observations to 8-month surrogates in RCT.
INTRODUCTION: Cardioprotective effects of erythropoietin (EPO) on infarcted myocardium in acute myocardial infarction (AMI) patients have been inconclusive. This study aimed to assess the effect of EPO administration on coronary microvascular dysfunction (CMD) and myocardial viability in anterior AMI. We also evaluated the serial changes in CMD and cardiac remodeling in these patients. METHODS: Patients with a successful percutaneous coronary intervention (PCI) for the first anterior AMI were randomly assigned to two groups (EPO and control groups), and given single-dose intravenous administration of recombinant human EPO (12,000 IU) or saline after PCI. Delayed-enhanced cardiac magnetic resonance imaging was performed at 1 week after AMI to assess the average of transmural extent of infarction and infarct size. Coronary flow velocity reserve (CFVR) of the left anterior descending coronary artery was measured by Doppler echocardiography at 1 week, 1 month, and 8 months after AMI. All patients underwent clinical follow-up for the assessment of cardiac remodeling. RESULTS: Sixty-one patients (EPO 32, control 29) were eligible for analysis. EPO group (2.4 ± 1.2) had a tendency of smaller transmural extent of infarction than that of control group (2.9 ± 1.1; p = 0.063). CFVR-8 months improved significantly in EPO group (2.9 ± 0.6) compared to control group (2.6 ± 0.5; p = 0.04). Left atrial (LA) volume - 8 months was significantly lower in EPO group (47 ± 11) than those of control group (65 ± 20; p = 0.004). CONCLUSIONS: A single medium dose of EPO could have a favorable effect on CMD and LA remodeling in the chronic phase of anterior AMI. TRIAL REGISTRATION: The institutional ethics committee of Wakayama Medical University, identifier, 1125.
No takes yet. Share an insight, caveat, or question.
Orii et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: